1. Home
  2. BDSX vs BEAT Comparison

BDSX vs BEAT Comparison

Compare BDSX & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BDSX
  • BEAT
  • Stock Information
  • Founded
  • BDSX 2005
  • BEAT 2015
  • Country
  • BDSX United States
  • BEAT United States
  • Employees
  • BDSX N/A
  • BEAT N/A
  • Industry
  • BDSX Precision Instruments
  • BEAT Retail: Computer Software & Peripheral Equipment
  • Sector
  • BDSX Health Care
  • BEAT Technology
  • Exchange
  • BDSX Nasdaq
  • BEAT Nasdaq
  • Market Cap
  • BDSX 53.0M
  • BEAT 57.6M
  • IPO Year
  • BDSX 2020
  • BEAT 2021
  • Fundamental
  • Price
  • BDSX $6.57
  • BEAT $1.59
  • Analyst Decision
  • BDSX Strong Buy
  • BEAT Buy
  • Analyst Count
  • BDSX 5
  • BEAT 1
  • Target Price
  • BDSX $32.50
  • BEAT $8.00
  • AVG Volume (30 Days)
  • BDSX 276.0K
  • BEAT 73.9K
  • Earning Date
  • BDSX 11-03-2025
  • BEAT 11-07-2025
  • Dividend Yield
  • BDSX N/A
  • BEAT N/A
  • EPS Growth
  • BDSX N/A
  • BEAT N/A
  • EPS
  • BDSX N/A
  • BEAT N/A
  • Revenue
  • BDSX $76,556,000.00
  • BEAT N/A
  • Revenue This Year
  • BDSX $18.78
  • BEAT N/A
  • Revenue Next Year
  • BDSX $26.42
  • BEAT $19.35
  • P/E Ratio
  • BDSX N/A
  • BEAT N/A
  • Revenue Growth
  • BDSX 25.70
  • BEAT N/A
  • 52 Week Low
  • BDSX $3.44
  • BEAT $0.91
  • 52 Week High
  • BDSX $34.39
  • BEAT $3.48
  • Technical
  • Relative Strength Index (RSI)
  • BDSX 52.63
  • BEAT 46.89
  • Support Level
  • BDSX $5.84
  • BEAT $1.53
  • Resistance Level
  • BDSX $6.94
  • BEAT $1.67
  • Average True Range (ATR)
  • BDSX 0.61
  • BEAT 0.10
  • MACD
  • BDSX -0.27
  • BEAT -0.03
  • Stochastic Oscillator
  • BDSX 34.52
  • BEAT 19.71

About BDSX Biodesix Inc.

Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.

About BEAT Heartbeam Inc.

HeartBeam Inc is a medical technology company is focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.

Share on Social Networks: